Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Tennessee Retina
Study ID
NCT01857544
Phase
PHASE4
Status
Unknown

Conditions

  • Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept — DRUG
    Monthly 2.0mg Aflibercept Intravitreal Injection

Study Details

The purpose of this study is determine the number of patients with complete resolution of macular edema secondary to central retinal vein occlusion following 6 monthly injections of Aflibercept.

Key Dates

Start date
Jun 30, 2013
Status verified
Oct 2014
Primary completion
Jan 31, 2016
Completion
Mar 31, 2016

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Aflibercept 2.0mg
    Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.

Primary Outcome Measure

Complete anatomic resolution of macular edema following central retinal vein occlusion (CRVO) as measured by Optical Coherence Tomography (OCT) [ Time Frame: From baseline to Month 6 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Tennessee Retina, PCNashvilleTennessee37203-

Find similar trials in Nashville, TN

By research site
Tennessee Retina, PC· Nashville, TN

Related Studies